You are here: Industry Insights > Exscientia

News List

Oxford University to develop Alzheimer’s disease treatments with Exscientia pharmatimes
February 22, 2021
The Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) has announced a partnership with AI drug discovery company Exscientia on the development of therapies for Alzheimer’s disease.
Exscientia forms UK-US partnership to screen possible Covid-19 drugs pharmaceutical-technology
April 02, 2020
Artificial intelligence (AI) drug discovery company Exscientia has expanded its ongoing anti-viral drugs partnership with the UK’s national synchrotron facility Diamond Light Source and University of Oxford across the Atlantic Ocean.
Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery worldpharmanews
January 14, 2020
Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration.
Exscientia and GT Apeiron form AI drug discovery alliance pharmaceutical-technology
June 13, 2019
Exscientia has entered a multi-target partnership with China-based GT Apeiron Therapeutics.
Exscientia builds AI capability with Kinetic acquisition pharmaphorum
November 27, 2018
There is huge focus on the potential of artificial intelligence (AI) in drug discovery – and Exscientia is another UK company building its capability in this area.
Exscientia acquires Kinetic Discovery to build 'full stack' AI-driven drug discovery capabilities biospectrumasia
November 26, 2018
Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company.
Speeding up drug discovery with Artificial Intelligence biospectrumasia
September 07, 2017
Exscientia signed a 250 mn Euros deal with Sanofi in May.
Exscientia, GSK Enter into Drug Discovery Collaboration americanpharmaceuticalreview
July 04, 2017
Exscientia has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK).
Exscientia announces EUR250 Million collaboration pharmassia
May 25, 2017
Exscientia collaborates for a Multiple-Product Development and Licence Option Agreement with Sanofi.

Previous page 1 2 Next page